Kornimate/medical-research-clean huggingface dataset:
evaluation of stigma and related factors in fibromyalgia

Conditions: Fibromyalgia

Summary: stigmatization is especially studied in mental disorders such as schizophrenia. in recent years, different chronic diseases such as aids, tuberculosis, and diabetes have also been shown to decrease in quality of life due to the "stigma" of these patients.

stigmatization is especially studied in mental disorders such as schizophrenia. in recent years, different chronic diseases such as aids, tuberculosis, and diabetes have also been shown to decrease in quality of life due to the "stigma" of these patients. fibromyalgia patients with chronic widespread body pain and accompanying subjective fatigue, depression, and anxiety; although there is no objective pathology from the outside, it can be stigmatized in family life, work-life and health institutions they apply for the diagnosis of pain due to the intensive complaints. the fact that the subjective complaints seen without an objective pathology are so severe makes the management of these patients difficult. to reveal the presence of stigma in patients diagnosed with fibromyalgia compared with the healthy control group is the main aim of this study. it is the secondary purpose of this study to determine related factors such as gender, age, educational status, marital status, employment status, income level, pain duration, pain intensity, medications used, and social support received from patients' family and the environment. we hypothesize that this group of patients suffers more stigma and the quality of life decreases due to this stigma.

Eligibility criteria:
inclusion criteria: * patients over the age of 18 * to be diagnosed with fibromyalgia according to american college of rheumatology 2016 revised criteria exclusion criteria: * have been diagnosed and treated with fibromyalgia before * presence of any diagnosis that can cause secondary fibromyalgia (rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis) * the presence of anemia * vitamin d deficiency * presence of known endocrine, neurological and cardiac diseases * antidepressant use

Keywords: fibromyalgia social support stigma
hormone dynamics and bone mineral density in anorexia nervosa v. hypothalamic amenorrhea

Conditions: Anorexia Nervosa; Hypothalamic Amenorrhea; Obesity

Summary: the purpose of this study is to determine whether the hormone dynamics in women with anorexia nervosa and hypothalamic amenorrhea is related to bone loss in those populations.


Eligibility criteria:
inclusion criteria: * amenorrhea for at least three months (unless participating as healthy control) * normal tsh or free thyroxine (free t4). exclusion criteria: * a condition known to affect bone metabolism, including cushing's syndrome or renal failure, with the exception of bone fracture. * any medication known to affect bone metabolism within 3 months of the study, including estrogen and progestins. patients receiving depot medroxyprogesterone (depo-provera) will be excluded from participating for 6 months after their last injection. * pregnant and/or breastfeeding. * diabetes mellitus. * active substance abuse, including alcohol.

Keywords: healthy overweight obese anorexia nervosa weight cortisol hormone bone density bone osteopenia osteoporosis amenorrhea menses irregular stress depression exercise diet
lubiprostone for children with constipation

Conditions: Constipation - Functional

Summary: this study is for children with constipation. children who completed 3 months of treatment in the earlier study (nct02042183): * were invited to participate * will receive lubiprostone for 9 more months * will see if lubiprostone safely relieves their constipation if taken for a whole year


Eligibility criteria:
inclusion criteria: * has completed the 3-month placebo-controlled study (nct02042183) * will continue to abstain from taking concomitant medication (prescribed or over-the-counter) that affects gastrointestinal motility exclusion criteria: * has untreated faecal impaction at the time of rolling over into study * has significant change in medical status, newly diagnosed and uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, or other systemic disease * has demonstrated non-compliance with study protocol during the 3-month placebo-controlled study (nct02042183)
leo 32731 for the treatment of moderate to severe psoriasis vulgaris

Conditions: Psoriasis Vulgaris

Summary: a study of leo 32731 in the treatment of psoriasis vulgaris

this is an investigation of the efficacy of leo 32731 30 mg as compared to placebo after 16 weeks of oral treatment of psoriasis vulgaris

Eligibility criteria:
inclusion criteria: * signed and dated informed consent * aged between 18 years and 65. * males or females of non-childbearing potential. * clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis * have moderate to severe psoriasis vulgaris * candidates of systemic anti-psoriatic treatment and/or phototherapy exclusion criteria: * subjects with therapy resistant psoriasis * previously exposed to apremilast * systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris * systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris

Keywords: psoriasis
behavior intervention for weight loss for type 2 diabetes mellitus adults with obesity problem (bmi of ≥23kg/m2)

Conditions: Obesity; Diabetes Mellitus, Type 2; Behavior

Summary: this quasi-experimental study aims to determine the effectiveness of a health intervention (chance2act) on behaviour change to act for weight loss among overweight/obese type 2 diabetes adults. the main question it aims to answer is: - is the new health intervention (chance2act) effective in changing overweight/obese type 2 diabetes adults from not being ready to act, to take action to lose weight?


Eligibility criteria:
inclusion criteria: * t2dm patients under follow-up of government health clinics kuantan, pahang. * age between 20 - 65 years old. * body mass index of more or equal to 23 kg/m2. * in the stage of pre-contemplation, contemplation, or preparation stage of change based on the s-weights questionnaire. * able to understand, read and write in the malay language. * have access to smartphone devices and internet services. * have immediate family members (adults) who are living in the same household. exclusion criteria: * pregnant patients. * patients' advanced comorbidity that will affect participation in the study protocol (e.g. vision problem, unable to walk or physically unfit to stand up, advanced heart failure, or cancer). * patients with mental conditions which will affect understanding of the study protocol.
a web application to reduce heavy drinking in first-time dwi offenders

Conditions: Driving While Intoxicated; Driving Under the Influence; Heavy Drinking; Alcohol Abstinence

Summary: the overall objective of this project is to develop, evaluate, and disseminate a web application for first-time dwi offenders that will provide them with an age-appropriate brief motivational intervention (bmi) to motivate them to reduce their drinking and a cognitive behavioral intervention (cbi) for to help them achieve and maintain abstinence. the goal is to reduce heavy drinking and consequently the risk for future drunk driving. the specific objectives of this phase ii are: * completing the development of the right turns prototype based on feedback from the phase i pilot study participants. this includes: providing more structure and guidance as participants work in the tool box section of the program; simplifying the content of the tool box; further r\&d in the text messaging feature for 2nd and 3rd tier cellular providers; implement a customized pdf report function for progress reports from the program to users' probation officers (under control of the user); developing a follow-up component and outcome reports; and revising the videos in the tool box to reflect greater diversity and a younger population of drinkers. * conducting a randomized clinical trial of the program with first time dwi/dui offenders who are recruited locally, collecting follow-up data, analyzing the data, and reporting the results.


Eligibility criteria:
inclusion criteria: * be a first-time dwi offender * have a 5th grade reading level * has a computer with internet access at home * own a cell phone with text messaging exclusion criteria: * age less than 18 * recent history of uncontrolled psychotic or bipolar behavior * evidence of significant cognitive impairment from brain dysfunction (e.g., head injury)

Keywords: web application dwi intervention dui intervention experimental group: right turns + treatment as usual control group: treatment as usual
safety and efficacy of low dose mm-120 for adhd proof of concept trial

Conditions: ADHD; Attention Deficit Disorder

Summary: this study measures the safety and efficacy of repeated low dose mm-120 as treatment for adhd in adults: a multi-center, randomized, double-blind, placebo-controlled

this study is a multi-center, randomized, double-blind, placebo-controlled phase 2a study of low dose mm-120 (20 μg) compared with a placebo administered for 6 weeks (twice a week on a 3/4-day schedule). low dose mm-120 (20 μg) is about 20% of the dose typically consumed for recreational psychedelic purposes. there will be a 1:1 randomization, double-blind, to mm-120 or placebo with the aim to reach 26 evaluable patients in each of the 2 arms at week 6.

Eligibility criteria:
inclusion criteria: * male and female outpatients ≥ 18 and ≤ 65 years of age at screening * patients with the diagnosis of diagnostic and statistical manual of mental disorders-5 (dsm-5) adhd, as determined by clinical evaluation and confirmed by structured interview (mini). * adequate organ function. * able to understand the study procedures and understand risks associated with the study, and sign written informed consent to participate in the study. * must be willing to refrain from more than 6 standard alcoholic drinks a week, more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete. exclusion criteria: * past or present diagnosis of a primary psychotic disorder or first degree relative with a psychotic disorder. * past or present bipolar disorder (dsm-5). * any lifetime history of suicide attempt. * once informed consent form is signed, not willing or able to stop any prescription or non-prescription adhd medications. * use of investigational medication/treatment in the past 30 days. * patients with a positive urine drug screen with the exception of thc or its metabolites. * pregnant or nursing females.
the use of liposomal bupivacaine in tap blocks for women undergoing cesarean section

Conditions: Pain

Summary: this present investigation aims to determine whether a transversus abdominous plane(tap) block, utilizing liposomal bupivacaine (exparel), at the conclusion of a cesarean section decreases post-operative pain. the hypothesis is that performance of the tap block with liposomal bupivacaine will decrease post-operative narcotic use.


Eligibility criteria:
inclusion criteria: * patients \>18 years of age * scheduled cesarean section with or without bilateral tubal ligation * planned performance of a pfannenstiel incision * patients are schedule to have a cesarean section with a member of the women's health or maternal and fetal medicine departments at penn state university hershey s. medical center exclusion criteria: * history of opioid use * history of chronic pain syndrome * use of general anesthesia during cesarean delivery * postoperative sicu admission * postpartum hemorrhage (defined as an estimated blood loss of greater then 1,000ml upon completion of the cesarean section)

Keywords: postcesarean section postoperative
early diagnosis of neonatal sepsis

Conditions: Sepses, Neonatal

Summary: sepsis is defined as a systemic inflammatory response syndrome (sirs) associated with infection diagnosed either on microbiologic cultures or strong clinical evidence of an infection.

sepsis is defined as a systemic inflammatory response syndrome (sirs) associated with infection diagnosed either on microbiologic cultures or strong clinical evidence of an infection..worldwide, neonatal sepsis is responsible for 4 million deaths annually and 99% of them occur in developing countries.. . morbidity associated with sepsis includes sensorineural hearing loss, visual disturbances, seizures, and neurodevelopmental issues.. blood culture is considered as gold standard for diagnosis of sepsis. the ideal diagnostic test should be inexpensive, have quick results hematologic scoring system(hss) of rodwell et al. includes the following: a) white blood cell and platelet count b) white blood differential count c) nucleated red blood cell count (to correct wbc count) d) assessment of neutrophil morphology for degenerative changes. a modified hss(modified hematological scoring system) was developed by removing the repetitive parameters, adding a new parameter - nucleated rbc.

Eligibility criteria:
inclusion criteria: * newborns with history of prolonged rupture of membranes, maternal intrapartum fever or non specific signs of sepsis namely; neonatal fever or hypothermia , poor feeding ,lethargy, irritability, depressed neonatal reflexes ,respiratory distress including apnea or cyanosis,hypoxia,poor capillary perfusion,bradycardia,hypotension,pallor,edema,vomiting,diarrhea,abdominal distention, bulging anterior fontanelle,coma,seizures,unexplained jaundice, reduced suckling, bleeding problems,hypoglycemia,hyperglycemia or metabolic acidosis were included in the study exclusion criteria: * all the newborn babies with history of delayed cry, meconium aspiration, congenital anomaly, history of antibiotics administration prior to admission to the baby or mother, intrapartum and neonatal death in sibling with similar presentation will be excluded
sgm-101 in colorectal lung metastases

Conditions: Colorectal Cancer; Metastatic Colon Cancer

Summary: near-infrared fluorescence-guided oncologic surgery (fgos) with the use of a tumor specific tracer (sgm-101) developed by surgimab can provide valuable intra-operative information about tumor location and extensiveness. sgm-101 already proven to be safe and valuable in colorectal cancer. this study aims to prove feasibility for colorectal lung metastases.


Eligibility criteria:
inclusion criteria: 1. signed informed consent prior to any study-mandated procedure; 2. patients aged over 18 years old; 3. all women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment. 4. has the ability to communicate well with the investigator in the dutch language and willing to comply with the study restrictions. 5. diagnosed with lung metastasis of colorectal origin and scheduled for a resection. exclusion criteria: 1. history of any anaphylactic reaction; 2. other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma; 3. laboratory abnormalities defined as: 1. aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase) or alkaline phosphatase levels above 5 times the or; 2. total bilirubin above 2 times the uln or; 3. serum creatinine above 1.5 times the uln or; 4. platelet count below 100 x 109/l or; 5. hemoglobin below 4 mmol/l (females) or below 5 mmol/l (males); 6. known positive test for human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag) or hepatitis c virus (hcv) antibody or patients with untreated serious infections; 4. patients pregnant or breastfeeding (pregnancy should be ruled out by a pregnancy test within two weeks prior to administration of the conjugate); 5. any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives. 6. previous sgm-101 use
sch 727965 in patients with acute myelogenous leukemia and acute lymphoblastic leukemia (p04717am2)(terminated)

Conditions: Leukemia, Myeloid, Acute; Lymphoblastic Leukemia, Acute

Summary: participants with acute myelogenous leukemia (aml) will be randomized to sch 727965 or gemtuzumab ozogamicin. all participants with acute lymphoblastic leukemia (all) will receive sch 727965. part 1 of the study will determine the activity of sch 727965 treatment in participants with aml and participants with all. part 2 of the study will determine the activity of sch 727965 treatment in participants with aml who experienced disease progression after standard treatment with gemtuzumab ozogamicin during part 1.


Eligibility criteria:
inclusion criteria: * for participants with aml: * age \>=60 years, either sex, any race. * diagnosis of cd33-positive aml by world health organization criteria. * must be in first or second relapse, or have primary refractory or refractory disease at first salvage, and not be considered a candidate for transplant. * acute promyelocytic leukemia who has relapsed following treatment with both all trans retinoic acid (tretinoin) and arsenic trioxide-based therapy is eligible. * for participants with all: * age \>=18 years, either sex, any race. * diagnosis of all by world health organization criteria. * must be in first or second relapse, or have primary refractory or refractory disease at first salvage, and not be considered a candidate for potentially curative therapy. * eastern cooperative oncology group performance status of 0 or 1. * adequate hematologic, renal, and hepatic organ function and laboratory parameters. * receiving treatment with hydroxyurea or leukapheresis to reduce elevated white blood cell count to \<=30 x 10\^9 is eligible, provided hydroxyurea and leukapheresis are discontinued at least 24 hours before initiation of study drug. exclusion criteria: * known central nervous system leukemia. * previous hematopoietic stem cell transplantation. * previous treatment with sch 727965 or other cyclin-dependent kinase inhibitors. * for aml, previous treatment with gemtuzumab ozogamicin. * known hiv infection. * known active hepatitis b or c.
cognitive stimulation

Conditions: Substance Use Disorders

Summary: this research is being done to learn if computer tasks that challenge the brain (cognitively stimulating tasks) can improve memory and other types of thinking. the study will compare the effects of different versions of the computer tasks. it also will compare the task performance of different groups of people.


Eligibility criteria:
inclusion criteria: * age 18-55 * in methadone maintenance or healthy volunteers * healthy exclusion criteria: * axis i disorder (except substance abuse and dependence in methadone maintenance patients) * severe cognitive impairment * serious untreated medical condition
home assessment and initiation of antiretroviral therapy for hiv in malawi

Conditions: HIV

Summary: despite increasing availability of antiretroviral therapy (art) for hiv in high prevalence countries, the majority of people with hiv infection still initiate treatment at an advanced stage of disease. this leads to a high risk of death soon after hiv diagnosis. prompt hiv diagnosis is, therefore, necessary for both individual and public health benefit and is being strongly promoted as international and national policy in malawi. however timely hiv diagnosis may not in itself be sufficient to ensure art initiation: this is reflected by the relatively high proportion of individuals who defer treatment-seeking for months or years following diagnosis of hiv. here the researchers investigate the extent to which home assessment and initiation of art adds to the effectiveness of a home-based hiv testing and counseling strategy, using entry to, adherence with, and retention in hiv care as the outcome of interest.


Eligibility criteria:
inclusion criteria: * usual resident of an eligible cluster * has had a positive hiv test (regardless of source) and requests facilitated access to hiv care from the resident community counsellor * confirmatory hiv test is positive * no previous art treatment, or less than one month's treatment in the past (including pmtct interventions) and not currently receiving hiv care * no contraindications to receiving art (as defined by integrated management of adult illnesses, hiv department, who) * no acute danger signs requiring hospital referral * aged 18 years or older * written or witnessed informed consent to participate in the study exclusion criteria: * not a usual resident of an eligible cluster * no previous hiv test, or hiv infection not confirmed by home-based art nurse * already receiving art, or has had more than 1 month's treatment in the past * known contraindication to firstline art (known hypersensitivity, renal failure, chronic liver disease) * acute danger sign present (as defined by integrated management of adult illnesses, hiv department, who) * age younger than 18 years * not willing to accept home-based art initiation * suspected or confirmed tb disease will not be an exclusion criteria, but will be an indication for deferral, until completion of the screening algorithm, with initiation of tb treatment if indicated.

Keywords: hiv aids antiretroviral therapy community-based study cluster-randomised trial hiv testing africa
comparison of two basal insulins for patients with type 2 diabetes (iooy)

Conditions: Diabetes Mellitus Type 2

Summary: the purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ilps) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. a gatekeeper strategy will be employed for sequentially testing the secondary objectives.


Eligibility criteria:
inclusion criteria: 1. have type 2 diabetes mellitus for at least 1 year. 2. are at least 18 years old. 3. have been receiving oral antihyperglycemic medications (oams), without insulin, for at least 3 months immediately prior to the study and have been on stable doses of at least 2 of the following oams for the 6 weeks prior to visit 1, at or above the doses defined in the following: metformin--1500 milligrams per day (mg/day); sulfonylureas--1/2 the maximum daily dose, according to the local package insert; dipeptidyl peptidase-intravenous (dpp-iv) inhibitors-- 1/2 the maximum daily dose, according to the local package insert; thiazolidinediones (tzds)--30 mg/day pioglitazone or 4 mg/day rosiglitazone. 4. have a hemoglobin a1c (hba1c) greater than or equal to 7.5% and less than or equal to 10.0%, as measured by a central laboratory before visit 2. 5. body mass index (bmi) greater than or equal to 25 and less than or equal to 45 kilograms per square meter (kg/m2). exclusion criteria 1. have used insulin therapy (outside of pregnancy) any time in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 weeks. 2. have taken any glucose-lowering medications not included in inclusion criterion \[3\] (for example, acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide) in the past 3 months before visit 1. 3. have had more than 1 episode of severe hypoglycemia, within 6 months prior to entry into the study, or is currently diagnosed as having hypoglycemia unawareness. 4. have a history of renal transplantation or are currently receiving renal dialysis or creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dl) (177 micromoles per liter \[micromol/l\]). 5. have obvious clinical signs or symptoms, or laboratory evidence, of liver disease (alanine transaminase \[alt\], or aspartate transaminase \[ast\] greater than 2 times the upper limit of the reference range, as defined by the local laboratory) or have albumin value above or below the normal reference range, as defined by the local laboratory.

Keywords: diabetes type 2